translat across mrt platform initi buy pt
believ mrt platform valid either clinic program
signific read-through diseas state translat
develop treatment diseas caus absenc
dysfunct protein gene use proprietari mrna
therapeut platform mrt deliv mrna encod
function protein therapeut bypass defect compani
util novel liposom encapsul nanoparticl specif target
mrna organ cell interest allow normal cellular
translat restor augment protein function initi two lead
program develop treatment cystic fibrosi cf
ornithin transcarbamylas defici otcd cf
initi inhal therapi phase trial began sad part
mad part anticip complet
over-the-counter second indic phase trial expect
initi view mrna platform excit new opportun
proven success either first two indic could
rapidli expand diseas categori although cf program
first target class mutat deriv nonsens mutat
success approach could believ ultim target
cf mutat even current treat modul therapi
initi coverag buy rate pt
enthusiasm compani cf program driven key
reason believ preclin data packag gener
compani thu far impress includ measur
protein express demonstr mani fold greater express
normal level believ compani long-term protein
express data potenti support dose everi
day compani shown broad lung distribut non-human
primat believ may predict broad dispers throughout
cf airway believ compani use lipid nanoparticl
capabl penetr lung mucu mesh reach airway
epithelium believ improv safeti profil mrna
therapi compar histor effort develop viabl gene therapi
treatment cf
continu next page
definit distribut analyst rate analyst certif disclosur pleas refer page report
otcd program provid second shot goal area limit standard care may eas potenti
concern regard deliveri expect compani phase sad/mad trial initi per protocol
evalu safeti toler otcd adult addit per studi protocol plasma ammonia
monitor measur safeti howev expect gain signific insight efficaci metric
subject still nitrogen scaveng therapi restrict diet prove safe
toler would anticip subsequ studi would allow patient care titrat scaveng therapi
address possibl effect mrna therapi importantli believ obviou structur differ
otcd liver deliveri distribut human liver significantli differ deliveri mous non-
human primat liver direct contrast concern deliveri mucus-obstruct lung cf studi
valuat risk invest thesi price target base equally-weight composit
multipl tax dilut ep discount back line
expect pe multipl discount rate earli development-stag biotechnolog compani npv
share discount cash flow analysi use discount rate growth rate line expect discount
growth paramet earli development-stag biotechnolog compani
compani overview catalyst
develop treatment diseas caus absenc dysfunct protein gene
use proprietari mrna therapeut platform mrt deliv mrna encod function protein
therapeut bypass defect compani util novel liposom encapsul nanoparticl
specif target deliveri mrna organ cell interest therebi allow normal cellular
translat restor augment protein function initi two lead program develop treatment
cystic fibrosi cf ornithin transcarbamylas defici otcd cf translat
initi inhal therapi phase trial began sad part mad trial part
anticip complet otcd second indic evalu otcd translat
develop intraven deliv reagent target liver phase trial expect initi
view mrna platform excit new opportun success either first two indic
could rapidli expand diseas categori moreov although cf program target class
mutat deriv nonsens mutat first believ success approach could ultim target
cf mutat even current treat modul therapi
figur import compani event horizon
 wainwright research compani report
reason enthusiast cf
preclin packag includ cftr messag protein express level demonstr mani fold
greater express normal level believ impress outcom
long-term protein express data believ may support dose everi day
demonstr broad lung dispers pattern nebul non-human primat airway
believ could lead broad distribut throughout cf lung
translat choic use lipid nanoparticl lnp deliveri vehicl believ valu
capabl lnp penetr mucu mesh reach airway epithelium
believ improv safeti profil mrna therapi compar gene therapi
modifi compani present
design deliv mrna encod fulli function cftr lung
target patient cf regardless underli genet mutat
current phase clinic trial patient cf
treat patient otcd
administr via intraven rout deliveri mrna encod fulli function ornithin
transcarbamylas over-the-counter liver
phase clinic trial patient otcd project initi first half
translat target cf patient avail
prior cf care predominantli consist pancreat enzym airway clearanc techniqu
antibiot exacerb palli care
vertex buy rate drug kalydeco ivacaftor approv first modul
potenti patient class gate mutat initi address approxim
subsequ kalydeco approv class iv mutat may
expand cover patient young year age august
orkambi vertex consist potenti kalydeco corrector lumacaftor
approv class ii patient homozyg heterozyg residu function
mutat
symdeko kalydeco tezacaftor vertex approv larg consid
improv orkambi lack signific bronchoconstrict lack
lumacaftor mediat ddi lower effect ivacaftor moreov symdeko consid better
foundat tripl therapi
vertex tripl consist symdeko demonstr posit outcom two phase
studi vertex tripl pend complet anticip approv
tripl modul therapi avail nearli peopl cf mutat cystic
current class nonsens stop mutat patient compris remain cf popul
lack approv therapi correct basic defect cftr
three possibl approach treat nonsens mutat
due absenc function cftr protein nonsense/stop mutat three convent
approach use address patient
read-through agent amino-glycosid bypass stop mutat gener normal
gene therapi involv repair replac incorrect sequenc dna within gene
mrna therapi involv replac defect mrna case absent mrna
mrna product function ident normal error-fre version
design deliv mrna encod fulli function cftr cf lung class
aminoglycosid investig potenti
read-through therapi class cf patient
aminoglycosid induc conform chang within ribosom allow codon-anticodon mismatch
therebi allow read-through prematur termin codon use howev limit less
ideal safeti profil includ kidney toxic possibl hear loss
principl read-through well-develop shown effect indic
 ataluren develop therapeut rate approv eu treatment
nonsens mutat patient duchen muscular dystrophi
mechan action ataluren well develop numer report confirm activ
work develop ataluren read-through agent class cf patient well trial
howev consist variabl controversi respect outcom includ question regard
geograph trial differ use inhal antibiot potenti toxic
march compani announc ataluren confirmatori phase trial act cf nonsens
mutat achiev either primari secondari endpoint program discontinu
lead hypothesi propos regard variabl previou ataluren studi
aminoglycosid tobramycin novarti nv rate bind compet ataluren ribosom
site thu cf patient tobi inhal formul tobramycin observ posit effect
current eloxx eloxx neutral rate develop modifi aminoglycosid read-
thorough agent cf accord manag select cytoplasm site may
therefor enhanc activ ataluren lack furthermor may also inhibit nonsens
mediat decay therebi gener full-length cftr messag translat
complet mad phase trial propos phase trial initi
opinion moa remain unsubstanti potenti therapi class cf patient thu leav
gene therapi mrna therapi viabl approach
gene therapi vs mrna therapi cf class
importantli gene therapi signific advantag success may one-tim treatment
de-facto term cure
con gene therapi approach often limit effici process difficulti deliv
requir reagent target tissu deliveri target cell within tissu gene insert
safeti concern potenti disrupt non-affect gene due random insert concern
even deliv insert correctli maintain exogen gene activ often difficult
potenti advantag mrna therapi includ requir enter cell nucleu need
alter genom mrna may use multipl mutat within gene substant
chang mutat agnost abil repeatedli dose therebi affect dose/concentr
desir protein
con limit mrna therapi includ difficulti deliveri target organ cell type
need repeatedli dose
histor review gene therapi approach cf
sinc clone cf gene nearli clinic trial studi approxim
cf patient use varieti agent ther
studi includ adenovir adeno-associ viral vector well recent lentivir
sendai viral vector well non-vir liposom mediat vector
list key mileston develop gene therapi
earli first vitro demonstr evid retrovir correct cftr perform
first evid adenovir cftr transfer anim rat occur cell
first adenovir cftr transfer human nasal epithelium occur year later natur
five-year clone cftr first dose escal perform reveal
shown repetit treatment adenovir vector result increas
express cftr clin invest
first trial non-vir lipid mediat vector conduct gene ther volume
demonstr repeat administr adeno-associ viru cf lung
final extens trial evalu non-vir liposom mediat gene therapi conduct
determin approach gener modest effect cf lung lancet respir
spite extens effort numer investig patient involv singl
approv gene therapi treatment cf
design translat mrna platform
mrt platform design rapidli effici substitut code region desir mrna
interest vector left panel figur platform therebi allow flexibl potenti scalabl
product mrna product demonstr success initi treatment strategi cf
otcd believ possibl indic could rapidli target
opinion success mrna therapi also depend develop effici deliveri
vehicl synthes mrna util proprietari lipid nanoparticl lnp
modifi target differ organ cell interest addit believ regardless preclin
success model system anim model valid util lnp must determin human
figur mrna cassett vector well lnp vehicl
believ three line preclin evid support move clinic trial cf
express fisher rat thyroid cell human nasal epitheli cell lack
cftr result express cftr protein function cftr measur electrophysiolog
transduct knockout ko cf rat demonstr improv nasal
potenti differ npd well dose proport increas mrna express
repeat dose non-human primat nhp demonstr extens distribut
throughout lung repeat dose week five week result detect
immunohistochemistri hcftr protein advers side effect
spite believ convinc preclin data packag still left one overwhelm
question regard correct cf lung
signific limit lack correl mrna level gener cftr protein
extens cftr function spite high level express report unclear
much mrna must transcrib dose gener level cftr protein
enough correct cf airway
show efficaci cell cultur model
preclin evid express cell human nasal epitheli cell lack
cftr result express cftr protein function cftr measur electrophysiolog
figur short-circuit current measur
cell measur
uss chamber assay show
defin current mediat
cftr stimul forskolin
camp activ cftr
addit cftr potenti
inhibit
cftr
combin activ
current
gener cftr
activ
like uss chamber experi
preclin evid express fisher rat thyroid cell human nasal epitheli
cell lack cftr result express cftr protein function cftr measur
assay consid preclin gold standard demonstr cftr activ cell
frequent use model sinc inher express cftr abl form confluent tight
epitheli monolay electrophysiolog studi typic result observ cell need
replic valid hbe cell although shown translat report perform
experi hbe cell well
seen figur current express rather larg nearli difficult compar
normal current sinc cell lack cftr contrast non-cf cell grown air-liquid interfac
condit gener approxim current normal condit unclear
genotyp hbe cell use experi howev data could inform respect
magnitud respons compar either class mutat cell
experi would permit translat determin level function cftr activ correl
express level success mrna gene therapi trial
yet still earli determin assay translat clinic outcom believ
howev use first data point correl provid success
one relev question respect cftr therapi much enough even
vertex compound absolut answer much correct cftr need alter
cf phenotyp opinion question may easili address success
preclin evid express fisher rat thyroid cell human nasal epitheli
cell lack cftr result express cftr protein function cftr measur
figur mrna level chlorid channel function
increas dose result
increas level hcftr express
epitheli membran detect
dose mg
result appear immatur
 suggest dose
suffici mrna gener
cftr process may
high protein express level cell cultur demonstr
preclin evid express fisher rat thyroid cell human nasal epitheli
cell lack cftr result express cftr protein function cftr measur
opinion data set import demonstr signific level cftr protein express
translat believ express strong indic
efficaci enthusiasm slightli blunt lack experi demonstr
similar effect cell express cell would allow direct comparison wild-typ
preclin assay remain unclear rate take cf airway
epitheli cell translat similarli effici cf intra-cellular environ data
present support move forward clinic trial
sustain high level cftr messag least day
preclin evid transduct cftr knockout ko rat demonstr improv
nasal potenti differ npd dose depend mrna express
figur increas hcftr mrna vs rat mrna
level instil
increas hcftr mrna
rat
time independ dose
still detect normal rat
mrna level day singl
administr highest dose
high level cftr messag anim model
suggest long-term durat effect
preclin evid transduct cftr knockout ko rat demonstr improv
nasal potenti differ npd dose depend mrna express
demonstr larg increas mrna product compar host rat mrna level measur
qpcr lowest dose mrna level still fold greater endogen rat mrna cftr
ko rat appear normal level messag fold increas express could also compar
normal transcript plo one data suggest may result cftr
protein level least compar normal wild-typ level
highest dose level mrna still detect day administr approxim time
level endogen ko rat cftr opinion data indic transcript function
day could suggest dose approxim month may feasibl
sinc express measur qpcr concern primer set use may differ
affin hcftr vs rcftr sequenc typic differ minim
result signific sourc error
express yield improv rat npd
preclin evid transduct cftr knockout ko rat demonstr improv
nasal potenti differ npd dose depend mrna express
instil
red symbol result
increas npd approxim
mvolt compar increas
cftr ko rat instil empti
given dose two week
either empti lnp
follow assess cftr
activ npd measur
express yield improv rat npd consider
preclin evid transduct cftr knockout ko rat demonstr improv
nasal potenti differ npd dose depend mrna express
opinion npd measur often difficult interpret due larg varieti factor may
affect outcom includ nasal cathet locat solut temperatur flow rate movement
anim inexperi investig encourag measur perform
laboratori dr steve row univers alabama birmingham well vers
techniqu somewhat cautiou howev due small number anim studi
rel small increas npd mvolt typic mv consid lowest level
respons consid beyond nois assay data statist signific
although highli inform right investig hand believ site site variabl npd
would make difficult assay use clinic trial moreov sinc deliv
inhal therapi believ suffici express level would achiev via retrograd
movement nasal epithelium use approach possibl bronchial pd perform
bronchoscopi may consid futur trial
broad distribut nhp lung suggest
readili dispers throughout lung
preclin evid repeat dose non-human primat nhp demonstr
effici distribut throughout lung repeat dose week five week result
detect immunohistochemistri hcftr advers side effect
figur mrna level measur nhp lung singl aerosol
dose compar normal nhp-specif cftr mrna level
hcftr mrna level
higher normal
nhp
observ
nebul
wide distribut express
lung
broad distribut nhp lung import addit data
necessari convinc us efficaci cf lung
preclin evid repeat dose non-human primat nhp demonstr
effici distribut throughout lung repeat dose week five week result
detect immunohistochemistri hcftr advers side effect
data demonstr capabl penetr nhp airway express
throughout lung level believ could support human correct
data somewhat limit due express rel healthi nhp subject may
compar well mucus-impact cf lung
moreov clear impact bronchiectasi airway remodel may
distribut patient patient variabl like also occur due sever diseas degre lung
kol note vertex oral therapi may benefici advantag due abil get
area affect cf lung
express gener long-last cftr protein nhp lung
preclin evid repeat dose non-human primat nhp demonstr
effici distribut throughout lung repeat dose week five week result
detect immunohistochemistri hcftr advers side effect
exposur
express hcftr translat
detect cftr protein
surfac epithelia lung
buffer instil hour singl nebul dose
 hour final dose
day recoveri period high multiple-dos administr
airway epithelium nhp lung
preclin evid repeat dose non-human primat nhp demonstr
effici distribut throughout lung repeat dose week five week result
detect immunohistochemistri hcftr advers side effect
although would difficult quantit compar stain hcftr nhp-cftr would
desir observ two signal parallel section
presum distribut lung would anticip signific limit
protein express
half-lif endogen hcftr protein approxim hour physiol cell
physiol believ detect hcftr protein day final nebul
dose suggest high level express sustain cftr express could
suggest less frequent dose regimen outcom observ human subject
design phase studi
figur phase sad mad trial design compani document
weekli dose
weekli dose
studi consist part current part sad initi enrol patient year old
older class ii cf mutat per protocol
target enrol patient expect major class mutat patient
per manag part mad expect initi
accord manag follow fda guidelin dsmb treat studi compar gene
therapi studi requir complet individu patient prior initi next patient
somewhat delay complet trial provid greatest safeti window
measur safeti outcom could possibl give insight efficaci
lowest dose test level fda agre may efficaci base lung
distribut express mrna copi number detect ish rat nhp model
success class mutat question remain prior
expans cf class mutat
abl expand cf mutat think answer base number differ
function differ wt-cftr modul correct cftr wt-cftr function stabl longer
correct cftr abl effect gener greater level mucociliari clearanc wt-cftr
prevent lung declin much cftr express need prevent declin restor normal rate
declin wt-cftr regul protein better correct cftr enac slc protein
aquaporin other ad modul therapi increas activ function
modul profound effect thu far correct class ii-v cftr mutat vertex tripl pois
significantli impact homozygot function patient provid doubl digit improv
lung function well signific gain sweat chlorid effect pulmonari exacerb
posit data yet clear normal correct cftr molecul biophys studi membran
resid time recycl rate yet complet likewis biophys properti mucu
adhes properti solid differ similar level wt-cftr mediat
express vs similar level correct cftr
shown effect class ii-v patient eager know therapi break thu far
perceiv ceil observ modul
compar studi use determin molecul function optim capac truli util
normal mrna advantag pharmacolog correct molecul may never attain
also like mutat best serv mrna correct wherea other fine modul
effect target entir lung
despit preclin data present inhal effect deliv part cf lung
 encourag robust dispers pattern nhp lung believ small size
lnp advantag could support uptak cf airway note cf kol believ
advantag oral vertex therapi abl impact area lung believ
capabl effect penetr deep lung well possibl howev may
region lung bronchiectasi develop area may inaccess inhal
therapi result observ clinic trial may reason pursu particl distribut studi
cf subject determin extent abil lnp effect penetr damag area lung
concern regard lack deliveri organ gi pancrea
cf patient die lung diseas non-lung symptom address suffici without correct
 nutrit supplement suffici gener weight gain improv
observ modul opinion posit impact weight gain follow modul treatment
cf subject anoth notabl outcom assess modul modestli affect lung
function orkambi symdeko assess sole abil improv lung function
interest us see patient respond qol survey cfq-r
improv
also wonder effect pulmonari exacerb ultim declin lung function well
correl frequenc pex cf patient success reduc rate pex
model us commerci launch cf
regard us cf market assum approxim patient annual growth
translat popul
model cf popul class mutat
model penetr cf class patient
class ii-v mutat account cf popul howev translat initi target
predomin class patient current avail therapi wherea class ii-v cover
modul thu choos model class stage may choos re-evalu class ii-v
mutat later date
current assum launch annual cost per patient
assign probabl success combin clinic regulatori adjust
revenu project accordingli assum po due excel distribut pattern nhp well
consist messag protein express shown across sever model system
assum eu us revenu adjust factor base eu cf preval treatment
penetr eu annual cost
taken collect assumpt yield probabl adjust world-wide revenu cf
grow
cff registri data wainwright calcul
otcd provid second shot goal
otcd metabol liver enzym disord result mutat over-the-counter gene common
urea cycl disord enzym over-the-counter combin carbamyl-phosph amino acid ornithin make
citrullin normal circumst key step elimin nitrogen form ammonia via urea
cycl excess ammonia act neurotoxin result symptom includ vomit refus eat
progress lethargi coma treat diseas lead develop delay intellectu
disabl liver damag ann neurol
otcd x-link diseas thu femal typic less sever less frequent affect male
sever form otcd neonat onset may observ earli birth follow
neo-nat present mani patient requir liver transplant six-month age missens alter amino
acid frame shift nonsens mutat result otcd inherit metab
less frequent symptom otcd begin later life late-onset form less sever form
occur male femal symptom includ episod delirium errat behavior reduc level
conscious headach vomit seizur patient partial otcd milder type otcd
present time life trigger event infect stress mutat less sever
form otcd typic result over-the-counter enzym reduc level activ ammonia
excret via urea cycl possibl
otcd estim frequenc live birth neurol
current standard limit
treatment otcd patient requir number step dietari dialysi liver transplant
dietari restrict aim limit amount protein intak avoid develop excess
ammonia infant place low protein high calori diet supplement essenti amino acid
individu otcd also benefit supplement arginin citrullin enhanc product
urea cycl intermedi
aggress treatment need hyperammonem episod progress vomit
increas lethargi hyperammonem coma develop case typic treat
case liver transplant may consid although liver transplant replac defect
liver form over-the-counter gene protein may post-op complic includ need
addit dietari restrict patient otcd treat ammonia scaveng
horizon rate compound buphenyl ravic valeant vrx rate compound
ammonul drug function bind nitrogen either glutamin glycin excret excess
nitrogen prevent chronic hyperammonemia
otcd mous model
figur protein express hotc singl multipl administr spf-
ash mice defici over-the-counter
weekli dose demonstr hotc activ level rise approxim murin over-the-counter level
activ measur base gener over-the-counter enzym product citrullin untreat salin
treat mice gener approxim citrullin level also correl low level murin
over-the-counter observ spf-ash mice salin lane panel
figur express result decreas level orot acid protect
ammonia accumul spf-ash mice
untreat spf-ash mice elev orot acid level normal follow treatment
 spf-ash anim unabl rapidli clear ip inject ammonia untreat histobar contrast
singl treatment result signific accumul plasma ammonia level untreat
data suggest dose effect prevent accumul orot acid
plasma may need dose everi week
demonstr protein express nhp liver
figur demonstr high protein express over-the-counter nhp liver
liver hour administr salin left panel right panel
measur over-the-counter activ difficult least part due dietari effect howev approxim
normal over-the-counter activ may protect genet genom major
heterozygot carrier assum activ asymptomat wherea low activ patient later
onset milder diseas statu
quantit measur thu express demonstr presenc signal
necessarili demonstr whether level express suffici correct diseas
translat current design phase trial
translat per manag initi phase sad/mad trial per protocol studi
evalu safeti toler otcd adult
per manag detail avail submiss ind expect
respons regul
per studi protocol plasma ammonia monitor measur safeti howev expect
gain signific insight efficaci metric subject still nitrogen scaveng therapi
dietari restrict patient care monitor treatment typic
experienc hyper-ammonia prove safe toler would anticip subsequ
studi would allow patient care titrat scaveng therapi assess possibl effect
contrast cf studi expect deliveri distribut human liver
significantli differ deliveri either mous nhp liver
believ high level express preclin model robust inhibit orot acid eas
entri liver cell suggest promis approach treatment otcd
figur compound develop otcd
ultragenyx rate
arcturu arct rate
biom tracker street account
aav agent develop ultragenyx pharmaceut advanc competit
current phase trial dose cohort ultragenyx report limit number patient
patient shown normal ureogenesi
hepastem/heparesc liver progenitor cell-bas therapi phase clinic develop promethera
bioscienc privat donor matur hepatocyt harvest cryopreserv prior deliveri
recipi may benefit transient partial function support treatment consid long-
term solut patient
model us commerci launch
assum current preval otcd approxim patient annual growth
translat popul
model penetr otcd translat patient
current assum launch annual cost per patient compar
orphan indic enzym replac therapi assign po combin clinic
regulatori adjust revenu project accordingli choos po due strong
preclin demonstr reduc ammonia accumul well believ may easi rout
deliveri liver
assum eu us revenu adjust factor base eu cf preval treatment penetr
eu annual cost
taken collect assumpt yield probabl adjust world-wide revenu otcd
grow
valuat invest risk
valuat method price target base equally-weight composit
multipl tax dilut ep discount back line
expect pe multipl discount rate earli development-stag biotechnolog compani npv
discount cash flow analysi use discount rate growth rate line
expect discount growth paramet earli development-stag biotechnolog compani
risk invest thesi target price
regulatori risk regulatori risk could receiv regulatori approv
product develop regulatori approv may delay applic submit
addit healthcar reform countri may impact potenti commerci sale
commerci risk commerci risk translat success market sell
pipelin product receiv regulatori approv current compani
market product need build sale market medic liaison team well establish
distribut infrastructur risk includ physician accept drug govern payor
reimburs line expect potenti government price control
clinic develop risk develop risk associ preclin clinic studi
potenti delay start trial current investig sever asset
clinic trial enrol may take signific amount time clinic trial trial may postpon
delay varieti reason addit outcom trial difficult predict could fail
number reason includ safeti efficaci
manufactur risk oper manufactur facil third-parti contract
manufactur reli manufactur agreement need implement commerci product
manufactur capac demand other expect increas develop
commerci could face issu time cost present risk well abil
manufactur consist product manufactur facil highli regul subject risk closur
financi risk incur oper loss sinc incept view may achiev
profit sever year compani could need rais capit futur sustain oper
addit stock biotechnolog compani like publicli trade compani subject market volatil
liquid risk small trade float
liabil risk translat product candid may caus undesir side effect properti could
result legal action taken subject trial commerci patient compani product liabil lawsuit
common biopharmaceut industri compani also vulner typic busi liabil
associ conduct busi litigi environ
intellectu properti risk translat reli patent trade secret protect product
competit biotechnolog industri litigi lawsuit consid normal part busi
court might uphold translat intellectu properti right though far could find
infring upon anoth parti properti right addit biotech firm could potenti find loophol translat
intellectu properti estat might enabl launch gener version translat product prior
expir patent protect product translat unabl obtain protect intellectu
properti right may abl compet effect commerci market
except per share valu
revenu
revenu
revenu
chang fair valu conting consider
accret redeem convert prefer unit
stock redempt valu
net loss attribut common stockhold
except patient number
us revenu cf probabl adjust
eu revenu cf probabl adjust
ww revenu cf probabl adjust
us revenu cf
class patient
patient
probabl success
us revenu cf probabl adjust
eu revenu cf
us cf pt
us treatmen penetr
us treament annual cost
eu revenu cf probabl adjust
except patient number
us revenu otcd probabl adjust
eu revenu otcd probabl adjust
ww revenu otcd probabl adjust
us revenu otcd
patient
probabl success
us revenu otcd probabl adjust
eu revenu otcd
us otcd pt
us treatmen penetr
us treament annual cost
eu revenu otcd probabl adjust
mm except per share valu
cash equival
prepaid expens current asset
properti equip net
total liabil redeem convert prefer unit
stock stockhold equiti deficit
current portion conting consider
current portion defer revenu
long-term portion conting consider
defer revenu net current portion
defer rent net current portion
redeem convert prefer stock seri
accumul comprehens incom loss
discount
sensit ep estim
discount
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori translat inc tbio-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein li wang watsek alicia yin ph certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst firm and/or research analyst household financi interest secur
includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc invest
bank servic within twelv month seek compens compani mention report
invest bank servic within three month follow public research report
firm make market inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
